CAG
BPMC

Crestwood Advisors Group’s Blueprint Medicines BPMC Stock Holding History

Crestwood Advisors Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,157
Closed -$917K – 575
2025
Q2 		$917K Sell
7,157
-473
-6% -$49.1K 0.02% 290
2025
Q1 		$675K Buy
+7,630
New +$744K 0.01% 309

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Crestwood Advisors Group's BPMC Position: Q3 2025 in Review

Crestwood Advisors Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 7,157 shares — an estimated $917K sold.

Crestwood Advisors Group first reported a position in BPMC in Q1 2025 and held it in 2 quarters. The position peaked at $917K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Crestwood Advisors Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Crestwood Advisors Group sold 7,157 Blueprint Medicines shares in Q3 2025, an estimated $917K.
  • Crestwood Advisors Group first reported a position in Blueprint Medicines in Q1 2025 and held it in 2 quarters.
  • Crestwood Advisors Group's Blueprint Medicines position peaked at $917K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Crestwood Advisors Group's 13F filing for Q3 2025, filed 7 Nov 2025.